Spyre Therapeutics, Inc.
SYRESpyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation, long-acting antibody therapies for inflammatory bowel disease (IBD) and rheumatic diseases.
Earnings
Next report
Aug 4, 2026 (In 6 days)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation, long-acting antibody therapies for inflammatory bowel disease (IBD) and rheumatic diseases. The company leverages half-life extension technologies and high-concentration formulations to create monotherapies and fixed-dose combinations designed for quarterly or twice-annual subcutaneous dosing. Its core value proposition lies in improving patient outcomes and compliance through superior potency, optimized pharmacokinetics, and multi-pathway combination treatments.
Clinical-stage innovator focused on redefining the standard of care in IBD through extended half-life antibodies and novel combination regimens.
Questions, answered.
- What is Spyre Therapeutics, Inc.'s market cap?
- Spyre Therapeutics, Inc. (SYRE) has a market capitalization of $8.7B and trades on NASDAQ.
- Who are Spyre Therapeutics, Inc.'s competitors?
- Spyre Therapeutics, Inc.'s key competitors include Johnson & Johnson, AbbVie, Pfizer, and others. These companies compete in similar markets and product categories.
- Who does Spyre Therapeutics, Inc. partner with?
- Spyre Therapeutics, Inc.'s notable partners include Paragon Therapeutics, WuXi Biologics.
- What subsidiaries does Spyre Therapeutics, Inc. have?
- Spyre Therapeutics, Inc.'s subsidiaries include Parapyre.
- Where is Spyre Therapeutics, Inc. headquartered?
- Spyre Therapeutics, Inc. is headquartered in United States of America and employs approximately 30 people. It has been publicly traded since 2016.